Optellum partners with GE Healthcare to improve lung health

The companies are seeking to address one of the largest challenges in the diagnosis of lung cancer: helping healthcare providers determine the malignancy of a lung nodule. (Getty/josefkubes)

GE Healthcare and Optellum, the leader in AI decision support for the early diagnosis and optimal treatment of lung cancer, have signed a letter of intent to collaborate on the advancement of precision diagnosis and the treatment of lung cancer. This marks another strategic partnership win for Oxford-based Optellum.

Together, the companies are seeking to address one of the largest challenges in the diagnosis of lung cancer: helping providers to determine the malignancy of a lung nodule (a suspicious lesion that may be benign or cancerous). The majority of incidentally detected pulmonary nodules present an indeterminate cancer risk, which means they are incredibly challenging for clinicians to diagnose and manage. This can lead to delayed treatment for cancer patients and invasive procedures for healthy people.

Optellum’s Virtual Nodule Clinic provides clinicians with valuable expert support. It identifies and scores the probability of malignancy in a lung nodule, which is key to determining whether biopsy is necessary, and accelerates diagnosis. It is the only FDA-cleared, AI-assisted diagnosis software for early-stage lung cancer, and has been shown to improve the sensitivity and specificity of malignancy assessments of indeterminate nodules — enabling pulmonologists and radiologists to make optimal clinical decisions.

Optellum's technology thus represents an excellent match for GE Healthcare's Edison intelligence platform, which is designed to help healthcare providers achieve greater efficiency, improve patient outcomes, and increase access to care.

There are three immediate outcomes from this agreement:

1. GE plans to collaborate with Optellum's sales team on the distribution of the Virtual Nodule Clinic.

2. GE plans to work to integrate Optellum's platform with AI solutions powered by GE Healthcare’s Edison platform.

3. The companies intend to bring results from Optellum's Lung Cancer Prediction AI into the existing workflow of various GE Healthcare technological pathways, including CT and PACS.

ZingPR and CubanEight collaborate to secure top-tier coverage in the USA and UK

Working together, the two firms targeted business, technology, and healthcare journalists to drive significant media coverage across two countries, reaching hospital administrators, physicians, and potential customers.